Glaxo Wellcome Inc. v. Genentech, Inc.
46 F. App'x 964
CourtCourt of Appeals for the Federal Circuit
DecidedSeptember 13, 2002
DocketNo. 01-1386
StatusPublished
This text of 46 F. App'x 964 (Glaxo Wellcome Inc. v. Genentech, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Bluebook
Glaxo Wellcome Inc. v. Genentech, Inc., 46 F. App'x 964 (Fed. Cir. 2002).
Opinion
ORDER
GLAXO WELLCOME INC. files a stipulation and motion to dismiss the appeal pursuant to Federal Rule of Appellate Procedure 42(b).
The parties having so agreed, it is
ORDERED that the motion is granted and the proceeding is DISMISSED with prejudice under Federal Rule of Appellate Procedure 42(b). Each party to bear its own fees and costs.
Free access — add to your briefcase to read the full text and ask questions with AI
Cite This Page — Counsel Stack
Bluebook (online)
46 F. App'x 964, Counsel Stack Legal Research, https://law.counselstack.com/opinion/glaxo-wellcome-inc-v-genentech-inc-cafc-2002.